Corvus Pharmaceuticals Inc (CRVS)
1.95
+0.03
(+1.56%)
USD |
NASDAQ |
May 06, 16:00
2.09
+0.14
(+7.18%)
After-Hours: 19:43
Corvus Pharmaceuticals Net Income (Quarterly): -6.653M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -6.653M |
| September 30, 2023 | -6.00M |
| June 30, 2023 | -6.503M |
| March 31, 2023 | -7.873M |
| December 31, 2022 | -9.816M |
| September 30, 2022 | -14.83M |
| June 30, 2022 | -8.363M |
| March 31, 2022 | -8.297M |
| December 31, 2021 | -9.236M |
| September 30, 2021 | -10.67M |
| June 30, 2021 | -11.75M |
| March 31, 2021 | -11.58M |
| December 31, 2020 | 27.35M |
| September 30, 2020 | -9.796M |
| June 30, 2020 | -10.61M |
| March 31, 2020 | -12.94M |
| December 31, 2019 | -11.05M |
| September 30, 2019 | -11.00M |
| Date | Value |
|---|---|
| June 30, 2019 | -12.98M |
| March 31, 2019 | -11.64M |
| December 31, 2018 | -10.51M |
| September 30, 2018 | -10.50M |
| June 30, 2018 | -11.63M |
| March 31, 2018 | -14.30M |
| December 31, 2017 | -11.93M |
| September 30, 2017 | -12.72M |
| June 30, 2017 | -14.98M |
| March 31, 2017 | -16.04M |
| December 31, 2016 | -11.09M |
| September 30, 2016 | -10.30M |
| June 30, 2016 | -8.645M |
| March 31, 2016 | -6.347M |
| December 31, 2015 | -6.039M |
| September 30, 2015 | -3.151M |
| June 30, 2015 | -20.23M |
| March 31, 2015 | -1.913M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-14.83M
Minimum
Sep 2022
27.35M
Maximum
Dec 2020
-8.032M
Average
-9.816M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | -5.271M |
| Arbutus Biopharma Corp | -19.31M |
| Oragenics Inc | -12.75M |
| Relmada Therapeutics Inc | -25.17M |
| MAIA Biotechnology Inc | -6.257M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.651M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 67.01M |
| Earnings Yield | -28.72% |